Sign in with your email address username.


[Comment] Eribulin in soft-tissue sarcoma

Sarcomas are unusual tumours that can occur at any anatomical site. Although they account for less than 1% of malignant tumours, they can be divided into more than 50 clinically and biologically distinct subtypes. Until recently, all soft-tissue sarcomas were treated the same way, but in the past decade, progress has been made in identifying clinical, histological, and molecular features to guide management.1 In a randomised open-label phase 3 trial in The Lancet, Patrick Schöffski and colleagues2 report that eribulin improves overall survival in patients with advanced leiomyosarcoma and liposarcoma.